Liver Transplantation as a Primary Indication for Intrahepatic Cholangiocarcinoma: A Single-Center Experience

Abstract Background Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for orthotopic liver transplantation (OLT). The present study describes our institutional experience with patients who underwent transplantation for ICC as well as those with ICC who underwent transplantati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2008-11, Vol.40 (9), p.3194-3195
Hauptverfasser: Sotiropoulos, G.C, Kaiser, G.M, Lang, H, Molmenti, E.P, Beckebaum, S, Fouzas, I, Sgourakis, G, Radtke, A, Bockhorn, M, Nadalin, S, Treckmann, J, Niebel, W, Baba, H.A, Broelsch, C.E, Paul, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3195
container_issue 9
container_start_page 3194
container_title Transplantation proceedings
container_volume 40
creator Sotiropoulos, G.C
Kaiser, G.M
Lang, H
Molmenti, E.P
Beckebaum, S
Fouzas, I
Sgourakis, G
Radtke, A
Bockhorn, M
Nadalin, S
Treckmann, J
Niebel, W
Baba, H.A
Broelsch, C.E
Paul, A
description Abstract Background Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for orthotopic liver transplantation (OLT). The present study describes our institutional experience with patients who underwent transplantation for ICC as well as those with ICC who underwent transplantation with the incorrect diagnosis of hepatocellular carcinoma (HCC). Patients and Methods Data corresponding to ICC patients were reviewed for the purposes of this study. Patients with hilar cholangiocarcinoma and incidentally found ICC after OLT for benign diseases were excluded from further consideration. Results Among the 10 patients, 6 underwent transplantation before 1996 and 4 after 2001. Those who underwent transplantation in the early period had a preoperative diagnosis of inoperable ICC (n = 4) and ICC in the setting of primary sclerosing cholangitis (n = 2). In the latter period the subjects had a diagnosis of HCC in cirrhosis (n = 3) or recurrent ICC after an extended right hepatectomy (n = 1). Median survival was 25.3 months for the whole series and 32.2 months (range, 18–130 months) when hospital mortality was excluded (n = 3). Four patients are currently alive after 30, 35, 42, and 130 months post-OLT, respectively. Two patients died of tumor recurrence at 18 and 21 months post-OLT, respectively. One-, 3-, and 5-year survival rates were 70%, 50%, and 33%, respectively. Conclusions The role of OLT in the setting of ICC may be re-evaluated in the future under strict selection criteria and with prospective multicenter randomized studies. Potential candidates to be included are those with liver cirrhosis and no hilar involvement who meet the Milan criteria for HCC.
doi_str_mv 10.1016/j.transproceed.2008.08.053
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69797810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0041134508011317</els_id><sourcerecordid>69797810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-666fbc37e550dfe88301af6324d9177945587577d8c1e310bde37c52fa2186bd3</originalsourceid><addsrcrecordid>eNqNUlFrFDEQDqLY8_QvyCLYtz0zyW6S7YNQzmoLBwqtzyGXnW1z7iZnslfsvzfbPUrxSRgYZvLNNzNfhpAPQFdAQXzarcZofNrHYBHbFaNUrSar-QuyACV5yQTjL8mC0gpK4FV9Qt6ktKM5ZhV_TU6goUAZhwUZNu4eY3HzSNgbP5rRBV-YVJjiR3SDiQ_FlW-dnfNdiDnM7e9wnzO2WN-FXHXrgjXROh8Gc1acF9fO3_ZYrtGPmfzizx6jQ2_xLXnVmT7hu6Nfkp9fL27Wl-Xm-7er9fmmtJXgYymE6LaWS6xr2naoFKdgOsFZ1TYgZVPVtZK1lK2ygBzotkUubc06w0CJbcuX5HTmzRr9PmAa9eCSxT6PiuGQtGhkIxXQDDybgTaGlCJ2ej8vrYHqSWy908_F1pPYerKa5-L3xy6H7ZDfnkqP6mbAxyPAJGv6LhNZl55wjCopIG-3JF9mHGZN7h1GneyjXq2LaEfdBvd_83z-h8b2zuev63_hA6ZdOESfVdegE9NUX0_nMV0HVTR7kPwv0Z65_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69797810</pqid></control><display><type>article</type><title>Liver Transplantation as a Primary Indication for Intrahepatic Cholangiocarcinoma: A Single-Center Experience</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sotiropoulos, G.C ; Kaiser, G.M ; Lang, H ; Molmenti, E.P ; Beckebaum, S ; Fouzas, I ; Sgourakis, G ; Radtke, A ; Bockhorn, M ; Nadalin, S ; Treckmann, J ; Niebel, W ; Baba, H.A ; Broelsch, C.E ; Paul, A</creator><creatorcontrib>Sotiropoulos, G.C ; Kaiser, G.M ; Lang, H ; Molmenti, E.P ; Beckebaum, S ; Fouzas, I ; Sgourakis, G ; Radtke, A ; Bockhorn, M ; Nadalin, S ; Treckmann, J ; Niebel, W ; Baba, H.A ; Broelsch, C.E ; Paul, A</creatorcontrib><description>Abstract Background Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for orthotopic liver transplantation (OLT). The present study describes our institutional experience with patients who underwent transplantation for ICC as well as those with ICC who underwent transplantation with the incorrect diagnosis of hepatocellular carcinoma (HCC). Patients and Methods Data corresponding to ICC patients were reviewed for the purposes of this study. Patients with hilar cholangiocarcinoma and incidentally found ICC after OLT for benign diseases were excluded from further consideration. Results Among the 10 patients, 6 underwent transplantation before 1996 and 4 after 2001. Those who underwent transplantation in the early period had a preoperative diagnosis of inoperable ICC (n = 4) and ICC in the setting of primary sclerosing cholangitis (n = 2). In the latter period the subjects had a diagnosis of HCC in cirrhosis (n = 3) or recurrent ICC after an extended right hepatectomy (n = 1). Median survival was 25.3 months for the whole series and 32.2 months (range, 18–130 months) when hospital mortality was excluded (n = 3). Four patients are currently alive after 30, 35, 42, and 130 months post-OLT, respectively. Two patients died of tumor recurrence at 18 and 21 months post-OLT, respectively. One-, 3-, and 5-year survival rates were 70%, 50%, and 33%, respectively. Conclusions The role of OLT in the setting of ICC may be re-evaluated in the future under strict selection criteria and with prospective multicenter randomized studies. Potential candidates to be included are those with liver cirrhosis and no hilar involvement who meet the Milan criteria for HCC.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2008.08.053</identifier><identifier>PMID: 19010231</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Bile Duct Neoplasms - surgery ; Bile Ducts, Intrahepatic - surgery ; Biological and medical sciences ; Cholangiocarcinoma - surgery ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatectomy ; Hospital Mortality ; Humans ; Liver Transplantation - mortality ; Liver Transplantation - physiology ; Liver, biliary tract, pancreas, portal circulation, spleen ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Retrospective Studies ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the digestive system ; Survival Rate ; Survivors ; Time Factors ; Tissue, organ and graft immunology ; Tumors</subject><ispartof>Transplantation proceedings, 2008-11, Vol.40 (9), p.3194-3195</ispartof><rights>2008</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-666fbc37e550dfe88301af6324d9177945587577d8c1e310bde37c52fa2186bd3</citedby><cites>FETCH-LOGICAL-c463t-666fbc37e550dfe88301af6324d9177945587577d8c1e310bde37c52fa2186bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041134508011317$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20876188$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19010231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sotiropoulos, G.C</creatorcontrib><creatorcontrib>Kaiser, G.M</creatorcontrib><creatorcontrib>Lang, H</creatorcontrib><creatorcontrib>Molmenti, E.P</creatorcontrib><creatorcontrib>Beckebaum, S</creatorcontrib><creatorcontrib>Fouzas, I</creatorcontrib><creatorcontrib>Sgourakis, G</creatorcontrib><creatorcontrib>Radtke, A</creatorcontrib><creatorcontrib>Bockhorn, M</creatorcontrib><creatorcontrib>Nadalin, S</creatorcontrib><creatorcontrib>Treckmann, J</creatorcontrib><creatorcontrib>Niebel, W</creatorcontrib><creatorcontrib>Baba, H.A</creatorcontrib><creatorcontrib>Broelsch, C.E</creatorcontrib><creatorcontrib>Paul, A</creatorcontrib><title>Liver Transplantation as a Primary Indication for Intrahepatic Cholangiocarcinoma: A Single-Center Experience</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Background Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for orthotopic liver transplantation (OLT). The present study describes our institutional experience with patients who underwent transplantation for ICC as well as those with ICC who underwent transplantation with the incorrect diagnosis of hepatocellular carcinoma (HCC). Patients and Methods Data corresponding to ICC patients were reviewed for the purposes of this study. Patients with hilar cholangiocarcinoma and incidentally found ICC after OLT for benign diseases were excluded from further consideration. Results Among the 10 patients, 6 underwent transplantation before 1996 and 4 after 2001. Those who underwent transplantation in the early period had a preoperative diagnosis of inoperable ICC (n = 4) and ICC in the setting of primary sclerosing cholangitis (n = 2). In the latter period the subjects had a diagnosis of HCC in cirrhosis (n = 3) or recurrent ICC after an extended right hepatectomy (n = 1). Median survival was 25.3 months for the whole series and 32.2 months (range, 18–130 months) when hospital mortality was excluded (n = 3). Four patients are currently alive after 30, 35, 42, and 130 months post-OLT, respectively. Two patients died of tumor recurrence at 18 and 21 months post-OLT, respectively. One-, 3-, and 5-year survival rates were 70%, 50%, and 33%, respectively. Conclusions The role of OLT in the setting of ICC may be re-evaluated in the future under strict selection criteria and with prospective multicenter randomized studies. Potential candidates to be included are those with liver cirrhosis and no hilar involvement who meet the Milan criteria for HCC.</description><subject>Bile Duct Neoplasms - surgery</subject><subject>Bile Ducts, Intrahepatic - surgery</subject><subject>Biological and medical sciences</subject><subject>Cholangiocarcinoma - surgery</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatectomy</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Liver Transplantation - mortality</subject><subject>Liver Transplantation - physiology</subject><subject>Liver, biliary tract, pancreas, portal circulation, spleen</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the digestive system</subject><subject>Survival Rate</subject><subject>Survivors</subject><subject>Time Factors</subject><subject>Tissue, organ and graft immunology</subject><subject>Tumors</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUlFrFDEQDqLY8_QvyCLYtz0zyW6S7YNQzmoLBwqtzyGXnW1z7iZnslfsvzfbPUrxSRgYZvLNNzNfhpAPQFdAQXzarcZofNrHYBHbFaNUrSar-QuyACV5yQTjL8mC0gpK4FV9Qt6ktKM5ZhV_TU6goUAZhwUZNu4eY3HzSNgbP5rRBV-YVJjiR3SDiQ_FlW-dnfNdiDnM7e9wnzO2WN-FXHXrgjXROh8Gc1acF9fO3_ZYrtGPmfzizx6jQ2_xLXnVmT7hu6Nfkp9fL27Wl-Xm-7er9fmmtJXgYymE6LaWS6xr2naoFKdgOsFZ1TYgZVPVtZK1lK2ygBzotkUubc06w0CJbcuX5HTmzRr9PmAa9eCSxT6PiuGQtGhkIxXQDDybgTaGlCJ2ej8vrYHqSWy908_F1pPYerKa5-L3xy6H7ZDfnkqP6mbAxyPAJGv6LhNZl55wjCopIG-3JF9mHGZN7h1GneyjXq2LaEfdBvd_83z-h8b2zuev63_hA6ZdOESfVdegE9NUX0_nMV0HVTR7kPwv0Z65_w</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Sotiropoulos, G.C</creator><creator>Kaiser, G.M</creator><creator>Lang, H</creator><creator>Molmenti, E.P</creator><creator>Beckebaum, S</creator><creator>Fouzas, I</creator><creator>Sgourakis, G</creator><creator>Radtke, A</creator><creator>Bockhorn, M</creator><creator>Nadalin, S</creator><creator>Treckmann, J</creator><creator>Niebel, W</creator><creator>Baba, H.A</creator><creator>Broelsch, C.E</creator><creator>Paul, A</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081101</creationdate><title>Liver Transplantation as a Primary Indication for Intrahepatic Cholangiocarcinoma: A Single-Center Experience</title><author>Sotiropoulos, G.C ; Kaiser, G.M ; Lang, H ; Molmenti, E.P ; Beckebaum, S ; Fouzas, I ; Sgourakis, G ; Radtke, A ; Bockhorn, M ; Nadalin, S ; Treckmann, J ; Niebel, W ; Baba, H.A ; Broelsch, C.E ; Paul, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-666fbc37e550dfe88301af6324d9177945587577d8c1e310bde37c52fa2186bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Bile Duct Neoplasms - surgery</topic><topic>Bile Ducts, Intrahepatic - surgery</topic><topic>Biological and medical sciences</topic><topic>Cholangiocarcinoma - surgery</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatectomy</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Liver Transplantation - mortality</topic><topic>Liver Transplantation - physiology</topic><topic>Liver, biliary tract, pancreas, portal circulation, spleen</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the digestive system</topic><topic>Survival Rate</topic><topic>Survivors</topic><topic>Time Factors</topic><topic>Tissue, organ and graft immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sotiropoulos, G.C</creatorcontrib><creatorcontrib>Kaiser, G.M</creatorcontrib><creatorcontrib>Lang, H</creatorcontrib><creatorcontrib>Molmenti, E.P</creatorcontrib><creatorcontrib>Beckebaum, S</creatorcontrib><creatorcontrib>Fouzas, I</creatorcontrib><creatorcontrib>Sgourakis, G</creatorcontrib><creatorcontrib>Radtke, A</creatorcontrib><creatorcontrib>Bockhorn, M</creatorcontrib><creatorcontrib>Nadalin, S</creatorcontrib><creatorcontrib>Treckmann, J</creatorcontrib><creatorcontrib>Niebel, W</creatorcontrib><creatorcontrib>Baba, H.A</creatorcontrib><creatorcontrib>Broelsch, C.E</creatorcontrib><creatorcontrib>Paul, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sotiropoulos, G.C</au><au>Kaiser, G.M</au><au>Lang, H</au><au>Molmenti, E.P</au><au>Beckebaum, S</au><au>Fouzas, I</au><au>Sgourakis, G</au><au>Radtke, A</au><au>Bockhorn, M</au><au>Nadalin, S</au><au>Treckmann, J</au><au>Niebel, W</au><au>Baba, H.A</au><au>Broelsch, C.E</au><au>Paul, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver Transplantation as a Primary Indication for Intrahepatic Cholangiocarcinoma: A Single-Center Experience</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>40</volume><issue>9</issue><spage>3194</spage><epage>3195</epage><pages>3194-3195</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Background Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for orthotopic liver transplantation (OLT). The present study describes our institutional experience with patients who underwent transplantation for ICC as well as those with ICC who underwent transplantation with the incorrect diagnosis of hepatocellular carcinoma (HCC). Patients and Methods Data corresponding to ICC patients were reviewed for the purposes of this study. Patients with hilar cholangiocarcinoma and incidentally found ICC after OLT for benign diseases were excluded from further consideration. Results Among the 10 patients, 6 underwent transplantation before 1996 and 4 after 2001. Those who underwent transplantation in the early period had a preoperative diagnosis of inoperable ICC (n = 4) and ICC in the setting of primary sclerosing cholangitis (n = 2). In the latter period the subjects had a diagnosis of HCC in cirrhosis (n = 3) or recurrent ICC after an extended right hepatectomy (n = 1). Median survival was 25.3 months for the whole series and 32.2 months (range, 18–130 months) when hospital mortality was excluded (n = 3). Four patients are currently alive after 30, 35, 42, and 130 months post-OLT, respectively. Two patients died of tumor recurrence at 18 and 21 months post-OLT, respectively. One-, 3-, and 5-year survival rates were 70%, 50%, and 33%, respectively. Conclusions The role of OLT in the setting of ICC may be re-evaluated in the future under strict selection criteria and with prospective multicenter randomized studies. Potential candidates to be included are those with liver cirrhosis and no hilar involvement who meet the Milan criteria for HCC.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>19010231</pmid><doi>10.1016/j.transproceed.2008.08.053</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1345
ispartof Transplantation proceedings, 2008-11, Vol.40 (9), p.3194-3195
issn 0041-1345
1873-2623
language eng
recordid cdi_proquest_miscellaneous_69797810
source MEDLINE; Elsevier ScienceDirect Journals
subjects Bile Duct Neoplasms - surgery
Bile Ducts, Intrahepatic - surgery
Biological and medical sciences
Cholangiocarcinoma - surgery
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Gastroenterology. Liver. Pancreas. Abdomen
Hepatectomy
Hospital Mortality
Humans
Liver Transplantation - mortality
Liver Transplantation - physiology
Liver, biliary tract, pancreas, portal circulation, spleen
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Retrospective Studies
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the digestive system
Survival Rate
Survivors
Time Factors
Tissue, organ and graft immunology
Tumors
title Liver Transplantation as a Primary Indication for Intrahepatic Cholangiocarcinoma: A Single-Center Experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T14%3A21%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20Transplantation%20as%20a%20Primary%20Indication%20for%20Intrahepatic%20Cholangiocarcinoma:%20A%20Single-Center%20Experience&rft.jtitle=Transplantation%20proceedings&rft.au=Sotiropoulos,%20G.C&rft.date=2008-11-01&rft.volume=40&rft.issue=9&rft.spage=3194&rft.epage=3195&rft.pages=3194-3195&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2008.08.053&rft_dat=%3Cproquest_cross%3E69797810%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69797810&rft_id=info:pmid/19010231&rft_els_id=1_s2_0_S0041134508011317&rfr_iscdi=true